Merck receives CRL for ridaforolimus

Wednesday 6 June 2012

Ridaforolimus, an investigational treatment for metastatic soft tissue or bone sarcoma, has been turned down by the US Food and Drug Administration. The sponsor, Merck & Co Inc, announced receipt of a complete response letter on 5 June 2012.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States